Novo Nordisk raises 2026 outlook

Novo Nordisk is trying to prove it still has a second act in obesity drugs. The company’s injectable hits — Wegovy for weight loss and Ozempic for diabetes — made it a mark(cnbc.com)king: an oral Wegovy pill launched in the U.S. this year sold much better than expected in its first full quarter, and that was enough for Novo to raise its 2026 outlook on May 6. (cnbc.com) ### Why did this quarter matter so much? Because Novo badly needed evidence that growth was not just stall(cnbc.com)o DKK 96.8 billion, and adjusted operating profit came in at DKK 32.86 billion, ahead of the company-compiled analyst forecast of DKK 28.74 billion. Novo then tightened its full-year pain forecast a bit — it now expects adjusted sales and operating profit to decline 4% to 12%, instead of 5% to 13%. (cnbc.com) ### What exactly changed? The pill showed up. This was the fi(cnbc.com)— almost double the Reuters-cited analyst estimate of DKK 1.16 billion. Novo also said the pill generated about 1.3 million prescriptions in the first three months of the year. That is the kind of launch investors were waiting to see. (cnbc.com) ### Why is a pill such a big deal? Because injections limit the audience, even when demand is huge. A pill is easier to prescribe, easier to start, and easier for some pat(cnbc.com) accounts for 65% of all new prescriptions in the U.S., calling it a turnaround. Novo also said, pending approvals, it plans to launch the pill outside the U.S. in the second half of 2026. (cnbc.com) ### But weren’t Novo’s numbers messy too? Yes — and this is the catch. The headline growth was flattered by(cnbc.com)t surged 65%, but on an adjusted basis sales fell 4% and profit fell 6%. So this was not a clean “everything is fixed” quarter. It was more like proof that one new product can offset some real pressure elsewhere. (cnbc.com) ### What pressure are we talking about? Mostly price and competition. Novo has cut prices on Wegovy injections in the U.S., which helped volume but(cnbc.com) is why investors reacted so strongly here — not because one quarter solved the rivalry, but because it suggested Novo can still trade lower prices for higher volume and maybe stabilize the business. (globalbankingandfinance.com) ### Does this change the bigger GLP-1 story? A bit. One investor quoted by Reuters said the earnings downgrade cycle may (cnbc.com)inners even if margins get squeezed. Turns out that was the real question hanging over Novo — not whether demand exists, but whether demand stays strong once prices come down and competitors crowd in. This quarter says yes, at least for now. (globalbankingandfinance.com) ### So what’s the bottom line? Novo Nordisk did not suddenly erase its problems. But it found a credible g(globalbankingandfinance.com)rge enough to move guidance, sentiment, and the balance of the obesity-drug race. (cnbc.com)